javascript:fnNewsSubmit( 'm', '202507311637007495f6e2c25b70_48', '202507311637007495f6e2c25b70', '48', '0', '0' );
The patent covers an optimized vector structure designed for large-scale production of replication-incompetent adenoviruses. This achievement follows similar patent approvals in South Korea, the United States, China, Japan, and Russia, with applications still under review in Vietnam, Indonesia, Thailand, and Brazil.
During the production of replication-incompetent adenoviral vectors, unintended generation of replication-competent adenoviruses can compromise product quality and safety. To address this issue, global pharmaceutical companies often develop specialized producer cell lines or use alternative adenovirus serotypes—methods that can be costly and increase reliance on foreign technologies.
Cellid’s patented technology reduces dependence on foreign platforms and supports the development of both its COVID-19 variant-targeted vaccine and BVAC immuno-oncology therapies.
Kang also emphasized the urgency of their work amid signs of a COVID-19 resurgence in Asia, including South Korea. “With Phase 3 clinical trial dosing completed, we are accelerating preparations for regulatory approval of our vaccine,” he said. “Through commercialization, we aim to bolster national vaccine sovereignty.”
Kim Kuk Ju, HEALTH IN NEWS TEAM
press@hinews.co.kr
